Skip to main content
SpringerLink
Log in

Cytokine Immuno-Gene Therapy for Treatment of Brain Tumors

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The prognosis for patients with an intracerebral (i.c.) neoplasm is poor. Conventional treatments such as surgery, radiation therapy and chemotherapy have done little to affect long-term survival, and new methods of treatment are urgently needed. In this report approaches involving cytokine gene therapy in treatment of malignant brain tumors are reviewed and contrasted to a strategy developed in this laboratory involving the use of allogeneic cells genetically modified to secrete cytokines. In our studies, mice with an i.c. glioma, melanoma or breast carcinoma treated solely by intratumoral injections with allogeneic cells genetically modified to secrete interleukin-2 (IL-2) were found to survive significantly longer than mice in various control groups. The anti-tumor response was mediated predominantly by T-cell subsets (CD8+ and NK/LAK cells). The injections resulted in the killing of only the neoplastic cells; non-neoplastic cells were unaffected. Experiments involving treatment of animals with i.c. tumor using subcutaneous injections of cytokine-secreting allogeneic cells in the presence of tumor antigens demonstrated no effect in prolonging survival in spite of the development of a vigorous systemic anti-tumor immune response. Of special interest, mice injected intracerebrally with the cytokine-secreting allogeneic cells alone exhibited no neurologic defect and there were no adverse effects on survival. The injection of cytokine-secreting allogeneic cells into the microenvironment of an i.c. tumor is hypothesized to induce an anti-tumor immune response capable of prolonging survival. This pre-clinical animal data directly translates into clinical treatments for patients with a malignant i.c. tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mahaley MS, Mettlin C, Natarajan N, Laws ER, Peace BB: National survey of patterns of care for brain-tumor patients. J Neurosurg 71: 826-836, 1989

    Google Scholar 

  2. Gabrilove JL, Jakubowski A: Hematopoietic growth factors: biology and clinical application. Monogr J Natl Cancer Inst 10: 73-77, 1990

    Google Scholar 

  3. Kelso A: Cytokines: structure function and synthesis. Curr Opinion Immunol 2(2): 215-225, 1989

    Google Scholar 

  4. Borden EC, Sondel PM: Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer 65(suppl 3): 800-814, 1990

    Google Scholar 

  5. Rosenberg SA, Lotze MT, Mule JJ: New approaches to the immunotherapy of cancer. Ann Intern Med 108: 853-864, 1988

    Google Scholar 

  6. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA: High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment-related morbidity and histologic findings. JAMA 256: 3117-3124, 1986

    Google Scholar 

  7. Pizza G, Viza D, DeVince C, Vichi-Pascuuchi JM, Busutti L, Bergami T: Intralymphatic administration of interleukin-2 (IL-2) in cancer patients: a pilot study. Cytokine Res 7: 45-48, 1988

    Google Scholar 

  8. Sama G, Collins J, Figlin R, Robertson P, Altrock B, Abels R: A pilot study of intralymphatic interleukin-2. II Clinical and biological effects. J Biologic Response Modifiers 9: 81-86, 1990

    Google Scholar 

  9. Gandolfi L, Solmi L, Pizza GC, Bertoni F, Muratori R, DeVinci C, Bacchini P, Morelli MC, Corrado G: Intratumoral echo-guided injection of interleukin-2 and cytokine-activated killer cells in hepatocellular carcinoma. Hepato-Gastroenterology 36: 352-356, 1989

    Google Scholar 

  10. Bubenik J, Viotenok NN, Kieler J, Prassolov VS, Chumakov PM, Bubenikova D, Simova F, Jandlova T: Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumors in nu/nu mice. Immunol Lett 19: 279-282, 1988

    Google Scholar 

  11. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky M, Simons JW, Karasuyama H, Vogelstein B, Frost P: Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell 60: 387-403, 1990

    Google Scholar 

  12. Gansbacher B, Zier K, Daniels B, Cronin K, Bannedi R, Gilboa E: Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1223, 1990

    Google Scholar 

  13. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama IL, Taniyama T, Sakata TA: Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci 86: 9456-9460, 1989

    Google Scholar 

  14. Tepper RI, Pattengale PK, Uder P: Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503-512, 1989

    Google Scholar 

  15. Yu JS, Burwick JA, Dranoff G, Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factortransduced tumor cells. Human Gene Ther 8: 1065-1072, 1997

    Google Scholar 

  16. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, Yu JS: The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res 62: 5657-5663, 2002

    Google Scholar 

  17. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE: Eradication of established intracranial rat gliomas by transforming growth factor ? antisense gene therapy. Proc Natl Acad Sci USA 93: 2909-2914, 1996

    Google Scholar 

  18. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186: 1177-1182, 1997

    Google Scholar 

  19. Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH: Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50: 158-164, 2002

    Google Scholar 

  20. Fakhrai H, Shawler DL, Gjerset R, Naviaux RK, Koziol J, Royston I, Sobol RE: Cytokine gene therapy with interleukin-2 transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Human Gene Ther 6: 591-601, 1995

    Google Scholar 

  21. Sobol RE, Fakhrai H, Shawler DL, Gjerset R, Dorigo O, Carson C, Khaleghi T, Kozio J, Shiftan TA, Royston I: Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2: 164-167, 1995

    Google Scholar 

  22. Kim TS, Cohen EP: Interleukin-2-secreting mouse fibroblasts transfected with genomicDNAfrom murine melanoma cells prolong the survival of mice with melanoma. Cancer Res 54(10): 2531-2535, 1994

    Google Scholar 

  23. Kim TS, Russell SJ, Collins MK, Cohen EP: Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int J Cancer 51(2): 283-289, 1992

    Google Scholar 

  24. Tahara H, Zeh HJ 3rd, Storkus WJ, Pappo I, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT: Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54(1): 182-189, 1994

    Google Scholar 

  25. Lichtor T, Glick PP, Kim TS, Hand R, Cohen EP: Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83: 1038-1044, 1995

    Google Scholar 

  26. Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP: Application of interleukin-2 secreting syngeneic/ allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 9: 464-469, 2002

    Google Scholar 

  27. Kim TS, Russell SJ, Collins MKL, Cohen EP: Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. lnt J Cancer 51: 283-289, 1992

    Google Scholar 

  28. Yamada G, Kitamura Y, Sonoda H, Harada H, Taki S, Mulligan RC, Osawa H, Diamanststein T, Yokoyama S, Taniguchi T: Retroviral expression of the human IL-2 gene in a murine T cell line results in a cell growth autonomy and tumorigenicity. EMBO J 6: 2705-2709, 1987

    Google Scholar 

  29. Colbere-Garapin F, Horodniceanu F, Kouritsky P, Garapin AC: A new dominant hybrid selective marker for higher eukaryotic cells. J Mol Biol 150: 1-14, 1981

    Google Scholar 

  30. Kim TS, Xu WS, Cohen EP: Immunization with interleukin-2/interferon-? double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma. Melanoma Res 5: 217-227, 1995

    Google Scholar 

  31. Sugden B, Marsh K, Yates J: A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol Cell Biol 5: 410-413, 1985

    Google Scholar 

  32. Gillis S, Ferm MM, Ou W, Smith KA: T cell growth factors: parameters of production and a quantitative microassay for activity. J Immunol 120: 2027-2032, 1978

    Google Scholar 

  33. Chomczynski P, Sacchi N: Single step method of RNA isolation by acid guanidinium-thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987

    Google Scholar 

  34. Robinson WA, lobe K, Stevens R: Central nervous system metastases in malignant melanoma. Cancer Treat Res 35: 155-163, 1987

    Google Scholar 

  35. Kim H, Rosenberg SA, Steinberg SM, Cole DJ, Weber JS: A randomized double blind comparison of the antiemetic efficacy of ondansetron and dropidol in patients receiving high dose interleukin-2. J Emphasis Tumor Immunol 16: 60-65, 1994

    Google Scholar 

  36. Birchfield GR, Rodgers GM, Girodias KW, Ward JH, Samlowski WE: Hypoprothrobinemia associated with interleukin-2 therapy. J lmmunother 11: 71-75, 1992

    Google Scholar 

  37. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt M, Matie C, Koutcher J, Gilboa E, Blasberg P: RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-?. Cancer Res 55: 1902-1910, 1995

    Google Scholar 

  38. Griffitt W, Glick RP, Lichtor T, Cohen EP: Survival and toxicity of an allogeneic cytokine-secreting fibroblast vaccine in the central nervous system. Neurosurgery 42: 335-340, 1998

    Google Scholar 

  39. Yu JS, Wei MX, Chiocca A, Martuza RL, Tepper RI: Treatment of glioma by engineered interleukin-4-secreting cells. Cancer Res 53: 3125-3128, 1993

    Google Scholar 

  40. Glick RP, Lichtor T, Kim TS, Ilangovan S, Cohen EP: Fibroblasts genetically engineered to secrete cytokines suppress tumor growth and induce antitumor immunity to a murine glioma in vivo. Neurosurgery 36: 548-555, 1995

    Google Scholar 

  41. Watts RG, Wright JL, Atkinson LL, Merchant RE: Histopathological and blood-brain barrier changes in rats induced by intracerebral injection of human recombinant interleukin-2. Neurosurgery 25: 202-208, 1989

    Google Scholar 

  42. Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ: Differential permeability of the blood brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 141: 1115-1124, 1992

    Google Scholar 

  43. Sampson, JH, Ashley DM, Archer GE, Fuchs HE, Dranoff G, Hale LP, Bigner DD: Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion. Neurosurgery 41: 1365-1372, 1997

    Google Scholar 

  44. Giezeman-Smits, KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH: Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 60: 2449-2457, 2000

    Google Scholar 

  45. Okada H, Villa L, Attanucci J, Erff M, Fellows WK, Lotze MT, Pollack IF, Chambers WH: Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells. Gene Ther 8: 1157-1166, 2001

    Google Scholar 

  46. Natsume A, Mizuno M, Ryuke Y, Yoshida J: Antitumor effect and cellular immunity activation by murine interferonbeta gene transfer against intracerebral glioma in mouse. Gene Ther 6: 1626-1633, 1999

    Google Scholar 

  47. Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, Lieberman F, Schiff D, Attanucci J, Edington H, Chambers W, Robbins P, Baar J, Kinzler D, Whiteside T, Elder E: Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Human Gene Ther 11: 637-653, 2000

    Google Scholar 

  48. Fakhrai H, Mantil J, Gramatikova S, Nicholson G, Murphy-Satter C, Krauss G, Poelstra R, Ruppert J, Sequeira P, Satter M, Kruse CA: Gene therapy of human gliomas with TGF-?2 antisense gene modified autologous tumor cells. A Phase I trial. Proceeding of the American Association for Cancer Research 41: 543, 2000

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurological Surgery, Rush Medical College, Cook County Hospital and Hektoen Institute for Medical Research, Chicago, IL, USA

    Terry Lichtor & Roberta P. Glick

Authors
  1. Terry Lichtor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberta P. Glick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lichtor, T., Glick, R.P. Cytokine Immuno-Gene Therapy for Treatment of Brain Tumors. J Neurooncol 65, 247–259 (2003). https://doi.org/10.1023/B:NEON.0000003654.83272.4a

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:NEON.0000003654.83272.4a

Search

Navigation